Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

Abstract

Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters. Materials and Methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis. Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors (p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) (p = 0.71 and p = 0.58, respectively). Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role.

MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9

“…Another study revealed that reduced expression of miR-451 increased chemoresistance in patients with metastatic castration-resistant prostate cancer by targeting NEDD9 [ 25 ]. Our work and other previous studies [ 13 , 27 , 28 ] have determined the role of NEDD9 in PAC. We show that high expression of NEDD9 is significantly correlated with clinical staging, lymph node metastasis, histologic stage, and significantly shorter survival time.…”

MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9&nbsp;

“…Another study revealed that reduced expression of miR-451 increased chemoresistance in patients with metastatic castration-resistant prostate cancer by targeting NEDD9. 25 Our work and other previous studies 13,27,28 have determined the role of NEDD9 in PAC. We show that high expression of NEDD9 is signi cantly correlated with clinical staging, lymph node metastasis, histologic stage and signi cantly shorter survival time.…”

Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT

“…Esra Arslan 1 Hale Aral 2 Tamer Aksoy 1 Çiğdem Usul Afşar 3 Senem Karabulut 4 Fadime Didem Can Trabulus 5 Rıza Umar Gürsu 6 Tevfik Fikret Çermik 1 Scoring for HER2; • Score 0: negative immunostaining, • Score 1: poor staining/staining lesser than 30%, • Score 2: Uniform/complete membranous staining, even if weak staining, • Score 3: Uniform staining of at least 30%.…”

“…NEDD-9 overexpression has been reported to be strongly correlated with cancer metastasis due to its regulatory property on cell migration. [3][4][5] Carcinoembryonic antigens (CEA) and carbohydrate antigens 15-3 (CA 15-3) are used in BC follow-up; however, their prognostic value is limited regarding its sensitivity and specificity. 6 The American Society of Clinical Oncology does not recommend them for the diagnosis, screening, staging, and treatment follow-up of BC.…”